ANTIPODES PARTNERS Ltd Invests $94,000 in Qiagen N.V. (NYSE:QGEN)

ANTIPODES PARTNERS Ltd acquired a new position in shares of Qiagen N.V. (NYSE:QGEN) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 2,345 shares of the company’s stock, valued at approximately $94,000.

Several other institutional investors and hedge funds also recently made changes to their positions in QGEN. Envestnet Portfolio Solutions Inc. grew its position in Qiagen by 3.6% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 9,816 shares of the company’s stock worth $438,000 after purchasing an additional 341 shares in the last quarter. Pitcairn Co. boosted its position in shares of Qiagen by 5.3% in the fourth quarter. Pitcairn Co. now owns 6,996 shares of the company’s stock valued at $312,000 after acquiring an additional 354 shares during the period. Exchange Traded Concepts LLC boosted its position in shares of Qiagen by 2.3% in the first quarter. Exchange Traded Concepts LLC now owns 17,825 shares of the company’s stock valued at $716,000 after acquiring an additional 395 shares during the period. Headlands Technologies LLC increased its position in shares of Qiagen by 2.0% in the fourth quarter. Headlands Technologies LLC now owns 19,823 shares of the company’s stock worth $883,000 after purchasing an additional 397 shares during the last quarter. Finally, LPL Financial LLC increased its position in shares of Qiagen by 2.6% in the fourth quarter. LPL Financial LLC now owns 17,240 shares of the company’s stock worth $768,000 after purchasing an additional 432 shares during the last quarter. Institutional investors own 70.00% of the company’s stock.

Qiagen Price Performance

QGEN stock traded up $0.97 during trading on Thursday, reaching $51.37. The company’s stock had a trading volume of 286,930 shares, compared to its average volume of 1,368,715. Qiagen N.V. has a 1 year low of $37.63 and a 1 year high of $51.58. The company has a quick ratio of 2.83, a current ratio of 3.37 and a debt-to-equity ratio of 0.40. The company has a market capitalization of $11.42 billion, a P/E ratio of 128.75, a price-to-earnings-growth ratio of 2.52 and a beta of 0.68. The company’s fifty day moving average is $46.38 and its 200-day moving average is $43.10.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.50 by $0.05. The business had revenue of $483.46 million for the quarter, compared to the consensus estimate of $465.66 million. Qiagen had a return on equity of 14.61% and a net margin of 4.68%. The company’s revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.44 EPS. On average, research analysts expect that Qiagen N.V. will post 2.26 earnings per share for the current fiscal year.

Qiagen Dividend Announcement

The business also recently declared a dividend, which was paid on Thursday, July 10th. Stockholders of record on Thursday, July 3rd were paid a dividend of $0.25 per share. This represents a dividend yield of 0.52%. The ex-dividend date of this dividend was Wednesday, July 2nd. Qiagen’s dividend payout ratio is presently 62.50%.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the company. Wall Street Zen upgraded Qiagen from a “buy” rating to a “strong-buy” rating in a research report on Thursday, May 15th. Bank of America upped their target price on Qiagen from $50.00 to $53.00 and gave the stock a “buy” rating in a report on Thursday, June 26th. Redburn Atlantic downgraded shares of Qiagen from a “buy” rating to a “neutral” rating in a research note on Friday, April 4th. Barclays initiated coverage on shares of Qiagen in a research note on Tuesday, June 24th. They issued an “overweight” rating and a $55.00 target price on the stock. Finally, Robert W. Baird increased their price objective on shares of Qiagen from $42.00 to $43.00 and gave the company a “neutral” rating in a research report on Monday, April 21st. Seven investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $49.40.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.